Vinorelbine in progressive unresectable low-grade glioma in children.

Cappellano, Andréa; Bouffet, Éric; Silva, Franklim Barboza da; Paiva, Premila; Alves, Michelle Teodoro; Cavalheiro, Sérgio; Silva, N. S.

doi:10.1200/jco.2011.29.15_suppl.9524

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, a randomized trial that compared carboplatin and vincristine with TPCV demonstrated higher event-free survival for patients treated with TPCV although the difference was not statistically significant [9]. Vinorelbine has also showed promise in progressive unresectable low-grade glioma with the advantage of low toxicity [10]. Despite treatment with carboplatin and vincristine, TPCV, and vinorelbine chemotherapy regimens and radiotherapy, our patient demonstrated symptomatic progression.…”

Section: Discussionmentioning

confidence: 66%

Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan

et al. 2021

View full text Add to dashboard Cite

Introduction: Low-grade neuroepithelial tumors are a heterogeneous group of central nervous system tumors that are generally indolent in nature but in rare instances can progress to include leptomeningeal dissemination. Case Presentation: We present a case of a patient with a low-grade neuroepithelial tumor of indeterminate type with symptomatic leptomeningeal dissemination despite 3 chemotherapy regimens and radiotherapy. Somatic targetable mutation testing showed an FGFR1_TACC1 fusion. Therapy with pazopanib/topotecan was initiated, and disease stabilization was achieved. He received pazopanib/topotecan for a total of 2 years and is now >2 years from completion of treatment and continues to do well with no evidence of disease. Discussion: This case highlights the utility of targetable mutation testing in therapeutic decision-making and the novel use of systemic pazopanib/topotecan therapy for refractory low-grade neuroepithelial tumor within the context of this clinical situation and specific mutation profile.

show abstract

Section: Discussionmentioning

confidence: 66%

Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan

et al. 2021

View full text Add to dashboard Cite

show abstract

“…VNR in children with progressive LGG and optic pathway glioma. 15,16 Additionally, a favourable safety profile in this population has been reported. Given the relatively long treatment duration and the advantages of oral administration for the patients' quality of life, oral VNR appears as an attractive candidate for the management of…”

Section: Introductionmentioning

confidence: 90%

“…Recently, Cappellano et al reported encouraging results for i.v. VNR in children with progressive LGG and optic pathway glioma 15,16 . Additionally, a favourable safety profile in this population has been reported.…”

Section: Introductionmentioning

confidence: 95%

“…Results: PK analysis included 36 patients with a median age (range) of 11 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17) years. Estimates of apparent oral clearance (CL/F), apparent volume of distribution (V/F), half-life (t 1/2 ) and their between-subject variability (CV%) at 60 mg m À2 dose level, were 472 L h À1 (51.8%), 7002 L (57.9%) and 10 h (21.0%), respectively.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low‐grade glioma

Hamimed

Gattacceca

André

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aims There is a crucial need for pharmacokinetic (PK) data on oral vinorelbine (VNR) in the paediatric population. The aim of this work was to assess the PK profile of orally administered VNR in children with recurrent/progressive primary low‐grade glioma (LGG). Methods A multicentre, open‐label, single‐arm intervention phase II study was conducted. Patients, aged between 6 and 18 years, with histologically confirmed recurrent or progressive primary LGG or non‐documented typical optic pathway tumours, were included. PK parameters were estimated by non‐compartmental analysis using Phoenix WinNonlin® software (version 8.0, Certara, Inc.). The influence of demographic and biological covariates on VNR PK parameters was investigated using a multivariate linear regression analysis. Results PK analysis included 36 patients with a median age (range) of 11 (6–17) years. Estimates of apparent oral clearance (CL/F), apparent volume of distribution (V/F), half‐life (t1/2) and their between‐subject variability (CV%) at 60 mg m−2 dose level, were 472 L h−1 (51.8%), 7002 L (57.9%) and 10 h (21.0%), respectively. Negligible accumulation of VNR between C1 and C2 was observed. CL/F and V/F were found to increase with body surface area (BSA) (P = .004). Lower area under the concentration–time curve (AUC) levels were observed among children in comparison to adults. Conclusion Higher doses may be necessary for children with LGG. BSA showed a significant impact on VNR systemic exposure. We believe that our findings will serve as a basis for further studies to better characterize the concentration–response relationships of VNR among paediatric patients.

show abstract

“…Finally, repeated administration of etoposide is associated with a significant risk of leukemia [116]. Studies are ongoing to confirm the promising results observed with single-agent vinblastine, vinorelbine or the combination of bevacizumab and irinotecan [117][118][119].…”

Section: Chemotherapymentioning

confidence: 96%

Optic pathway gliomas: a review

et al. 2013

View full text Add to dashboard Cite

Optic pathway gliomas account for 3-5% of all pediatric CNS tumors and represent the most common intrinsic optic nerve tumors. These tumors occur preferentially during the first decade of life and are particularly frequent in children with neurofibromatosis type 1. Although optic pathway gliomas are low-grade tumors, their behavior can be aggressive, and their management is often challenging. Their management includes observation, surgery, chemotherapy and radiation. The role of each modality is discussed as well as current and future developments in treatment, in particular targeted therapies that are currently being investigated.

show abstract

Vinorelbine in progressive unresectable low-grade glioma in children.

Cited by 6 publications

References 0 publications

Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan

Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan

Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low‐grade glioma

Optic pathway gliomas: a review

Contact Info

Product

Resources

About